Cerevel Selects Alucio's Beacon Scientific Exchange Platform to Enhance Medical Affairs Innovation
SAN FRANCISCO, Sept. 22, 2022 /PRNewswire-PRWeb/ -- Alucio™, a fast-growing provider of cloud-based software for the life sciences industry, today announced that the Cerevel Therapeutics Medical Affairs function has selected Alucio's Beacon scientific exchange platform. Cerevel is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including Parkinson's, epilepsy, schizophrenia, and panic disorder.
Through this agreement, Beacon will provide Cerevel's Medical Affairs teams with new capabilities to improve efficiency and enhance their engagement with thought leaders. More specifically, Cerevel will use Beacon's content management and on-demand publishing functionality to efficiently organize and distribute documents to the Medical Affairs field team, and to allow the customization of presentations for specific meetings.
Additionally, Beacon's omnichannel engagement capabilities will help enable Cerevel's MSLs to leverage the platform to enrich their virtual meetings, as well as to power in-person, tablet-based meetings where data service is unavailable. All activity on the Beacon platform will provide Cerevel with actionable insights, which will assist them in future education efforts and in building connections with various healthcare provider audiences.
Cerevel adds to Alucio's fast-growing roster of life science companies that have become Beacon customers. The platform can support both large and small pharma, biotech and medical device companies seeking to more efficiently manage and distribute scientific content, and to deepen their relationships with both medical key opinion leaders and payers.
"We are very excited to be working with a unique, fast-growing company like Cerevel," said Jeff Asada, Alucio's Co-Founder and CRO. "We admire their focus and commitment to providing improved treatments for devastating neuroscience diseases. We look forward to supporting and enhancing their team's efforts with our Beacon platform and to deepening our relationship over time."
About Alucio:
Alucio is dedicated to the development of innovative software applications specifically for the life sciences industry. Alucio's flagship product, Beacon, is a modern, cloud-based scientific exchange platform that enhances scientific dialogue and engagement between life science companies and healthcare professionals. For more information, please visit the company's website http://www.alucio.io or contact: Lisa Amin at [email protected] (925) 788-3533.
Media Contact
Lisa Amin, Alucio, 925-788-3533, [email protected]
SOURCE Alucio
Share this article